Comparative Pharmacology
Head-to-head clinical analysis: ROCEPHIN KIT versus TAZICEF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ROCEPHIN KIT versus TAZICEF.
ROCEPHIN KIT vs TAZICEF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ceftriaxone is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking, leading to cell lysis and death.
Ceftazidime is a third-generation cephalosporin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBP-3, leading to cell lysis and death.
Adult: 1-2 g IV or IM every 24 hours. Maximum 4 g/day for severe infections.
2 g intravenously every 8 hours for serious infections; 1 g intravenously every 8 hours for uncomplicated infections.
None Documented
None Documented
Terminal half-life 6-9 hours in healthy adults; prolonged to 12-15 hours in elderly and up to 30 hours in severe renal impairment (CrCl <10 mL/min).
2 hours (prolonged to 4-12 hours in renal impairment; anuria: 20-30 hours).
Renal (33-67% unchanged), biliary (40-50% as active drug and metabolites), fecal (minor).
Primarily renal (80-90% unchanged via glomerular filtration and tubular secretion); biliary/fecal <10%.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic